title: More on bevacizumab in hereditary hemorrhagic telangiectasia.
authors.forename: Frederique
authors.initials: F
authors.lastname: Retornaz
authors.forename: Yves
authors.initials: Y
authors.lastname: Rinaldi
authors.forename: Christophe
authors.initials: C
authors.lastname: Duvoux
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab